Your Ferritin Is Almost Zero. Your Doctor Wants to Wait.

Iron deficiency in pregnancy causes real harm. The evidence for IV iron is solid. The barrier is not clinical.

Iron deficiency without anemia is still iron deficiency. The evidence for treating it in pregnancy is clear. The access to IV iron is not. Here is what the data show.

A low ferritin level during pregnancy is not a laboratory curiosity. It is a clinical problem with a trajectory. Ferritin measures stored iron. When stores fall, the body begins borrowing from itself: first from the liver, then from muscle, then from red cell precursors.

By the time hemoglobin drops below 11 g/dL, iron deficiency has already been present for weeks or months. Waiting for that threshold to treat is not watchful waiting. It is delayed care.

The question is no longer whether iron deficiency in pregnancy matters.

It does.

The questions are who qualifies for IV iron, when, and why access remains so difficult even when the clinical picture is unambiguous.

What Iron Deficiency Actually Does in Pregnancy

Iron requirements increase roughly six-fold during pregnancy, from approximately 1 mg per day outside of pregnancy to 6 mg per day in the third trimester (1). Oral supplementation addresses part of this demand but is limited by absorption, tolerance, and compliance. The gut absorbs a fraction of what is swallowed, and side effects from oral iron, including nausea, constipation, and abdominal pain, lead many women to take it inconsistently or stop entirely.

Iron deficiency anemia affects an estimated 38% of pregnant women worldwide (2).

In the United States, Black and low-income women are disproportionately affected, a disparity driven by baseline dietary access and unequal access to prenatal care (3).

But the burden extends well beyond official anemia statistics. Iron depletion without anemia, meaning low ferritin with a still-normal hemoglobin, is not captured in those numbers.

The downstream consequences are documented.

Maternal anemia increases the risk of postpartum hemorrhage through impaired uterine contractility (4). Low postpartum iron stores are associated with a two- to four-fold increase in the odds of postpartum depression across multiple studies (5). Postpartum anemia has also been linked to impaired cognition, early cessation of breastfeeding, and fatigue severe enough to interfere with infant care (6). Neonatal iron stores depend on maternal iron status in the third trimester, when the majority of fetal iron transfer occurs (1). A depleted mother is more likely to deliver a neonate with depleted stores.

These are not speculative associations. They are consistent findings across observational data, and they argue for treating iron deficiency before hemoglobin collapses, not after.

The Evidence for IV Iron

ACOG Practice Bulletin Number 233 (2021) defines anemia in pregnancy as a hemoglobin below 11 g/dL in the first and third trimesters and below 10.5 g/dL in the second trimester (7). It recommends oral iron as first-line treatment and acknowledges IV iron as safe and effective for patients who do not respond to oral therapy, cannot tolerate it, or require rapid iron repletion. That threshold requirement, oral iron failure, is where the access problem begins.

A 2024 meta-analysis including six studies and 3,842 participants found that IV iron produced significantly higher hemoglobin compared to oral iron, with a pooled mean difference of 1.21 g/dL (95% CI 0.83 to 1.59), and was more than twice as likely to correct anemia (OR 2.47; 95% CI 1.69 to 3.61) (8). The efficacy advantage of IV iron over oral iron is not a fringe finding. It is replicated across randomized controlled trials and meta-analyses.

The safety concern most often cited is hypersensitivity. That concern is outdated in its severity framing. Older dextran-based formulations carried real anaphylaxis risk. Modern formulations do not. For ferric carboxymaltose, the adjusted anaphylaxis rate in Medicare data is 0.8 per 10,000 first doses (9). Serious reactions are rare, and they occur in settings already equipped to manage them. A 30-minute infusion with 30 minutes of monitoring does not require intensive care capacity. It requires a chair, a line, and a nurse familiar with the protocol.

Ferric carboxymaltose permits single-dose administration of up to 1,000 mg in a 15-minute infusion with a well-characterized safety profile across more than 8,000 subjects in clinical studies (10). The argument that IV iron is too risky for routine use in pregnancy is not supported by the pharmacovigilance data on modern formulations.

The rest of this post is for paid subscribers.